Health Bulletin 10/September/2022
Here are the top health news for the day:
Supporting the Public Interest Litigation (PIL) seeking adoption of a "Holistic Integrated Medicinal System" in India, the Yoga Guru Baba Ramdev's Patanjali Research Institute approached the Delhi High Court yesterday praying to become impleaded as a party in the petition.
Noting that the intervention application seeking impleadment in the petition was not on record, a bench of Chief Justice S C Sharma and S Prasad granted one week's time to the applicant institute to bring it on record, adds PTI.
A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot Cancer Institute physician/scientist.
Nearly 200 local people participated in the study, which was led by Richard Moore, M.D., director of the Wilmot Cancer Institute's Gynecologic Oncology program at the University of Rochester Medical Center. Results were published on Sept. 8, 2022, in the high-impact Obstetrics & Gynecology "Green" journal.
Reference:
Moore, Richard George MD et al , Malignancy Assessment Using Gene Identification in Captured Cells Algorithm for the Prediction of Malignancy in Women With a Pelvic Mass, Obstetrics and Gynecology, sep 2022 DOI: 10.1097/AOG.0000000000004927
Through a recent notice, the National Board of Examinations (NBE) has invited Applications for Foreign Medical Graduate Examination (FMGE) December 2022.
National Board of Examinations in Medical Sciences (NBEMS) shall conduct the FMGE December 2022 on 4th December 2022 on a Computer Based Platform at various test centres across the country.
Application form for FMGE December 2022 can only be submitted online at https://nbe.edu.in from 9th September 2022 (3 PM Onwards) to 29th September 2022 (Till 11:55 PM).
Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that the company has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19.
It is to be noted that Zenara Pharma has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month. The tablet, which will be sold under the brand name 'Paxzen', is being manufactured at Zenara's USFDA and EU approved state-of-the-art facility in Hyderabad.
Amid all the ongoing litigations concerning the National Medical Commission's order regarding Government fees in 50 percent medical seats in the private medical colleges, the Madras High Court bench has directed the NMC to reconsider its decision in this regard.
Although the High Court bench comprising of Chief Justice Munishwar Nath Bhandari and Justice N. Mala has upheld the constitutional validity of Section 10 (1) (i) of the NMC Act 2019, under which the concerned office memorandum was issued, it expressed its concern over the possibility of several seats going vacant because of the high fees in the other 50 percent seats in the self-financed institutes.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd